

RESTRICTED BENEFIT CRITERIA - SEEBRI®

PROVINCE/PROGRAM	INDICATION	CRITERIA
British Columbia SA	COPD	COPD that failed both Spiriva®Respimat ®and Incruse ®
New Brunswick SA	COPD	Moderate to severe symptomatic COPD Exacerbating COPD As part of an open triple therapy in COPD uncontrolled on LAMA/LABA or ICS/LABA
Newfoundland and Labrador SA	COPD	COPD symptomatic on PRN SABA COPD with a FEV ₁ <60% As part of an open triple therapy in symptomatic and exacerbating COPD patient with a FEV ₁ <60%
Nova Scotia EDS	COPD	Moderate to severe symptomatic COPD Exacerbating COPD As part of an open triple therapy in COPD uncontrolled on LAMA/LABA or ICS/LABA
Prince Edward Island SA	COPD	Moderate to severe symptomatic COPD Exacerbating COPD
Saskatchewan EDS	COPD	Symptomatic COPD with a FEV ₁ <60% COPD unresponsive to SABA or SAMA

ACO: asthma COPD overlap, COPD: chronic obstructive pulmonary disease, EDS: Exception Drug Status, ICS: inhaled corticosteroids, LABA: long-acting beta-agonist, LAMA: long-acting muscarinic antagonist, SA: Special Authorization, SABA: short-acting beta-agonist, SAMA: short-acting muscarinic antagonist,